The present study aimed to assess the clinical implications of TMB using a small and verified panel and established biomarkers (PD-L1 CPS, EBV, and MSI) to better characterize and select advanced gastric cancer patients who may benefit from immunotherapy. This evidence concerns the gene CD274 and gastric cancer.